Fennec Pharmaceuticals (TSE:FRX) Shares Down 0.3% – Here’s What Happened

Fennec Pharmaceuticals Inc. (TSE:FRX)’s stock price dropped 0.3% during trading on Thursday . The stock traded as low as C$8.55 and last traded at C$8.62. Approximately 200 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 2,031 shares. The stock had previously closed at C$8.65.

Wall Street Analyst Weigh In

Separately, Stephens raised Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.

Fennec Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17. The firm has a 50 day moving average of C$6.83 and a two-hundred day moving average of C$7.72. The stock has a market cap of C$235.84 million, a PE ratio of 86.20 and a beta of 0.25.

Insider Buying and Selling

In other Fennec Pharmaceuticals news, Senior Officer Robert Christopher Andrade acquired 15,816 shares of the stock in a transaction on Monday, November 18th. The shares were bought at an average price of C$3.43 per share, with a total value of C$54,248.88. 16.20% of the stock is owned by company insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.